Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
Because of conflicting reports on the prognosis of patients with c-kit receptor positive AML and lacking correlations with cytogenetic analyses, we prospectively evaluated the c-kit receptor expression in 917 AML patients (750 adult patients; 167 children) using flow cytometry and compared the results to the immunophenotype, morphological and cytogenetic findings as well as clinical outcome. Expression of the c-kit receptor was present in 63% of all AML investigated. Among these an immature immunophenotype was more frequent and 30% had a CD34+/CD15- and 37% a CD34+/CD14- phenotype, whereas only 9% and 10% showed these phenotypes in the c-kit receptor negative group, respectively. C-kit receptor expression ranged average in M0 and M1 subtypes (69% versus 70%) but was less pronounced among M5 subtypes (21%). Results of karyotyping were available in 280 patients. C-kit receptor expression occurred in 37 of 42 (88%) patients with favorable cytogenetic abnormalities such as t(8;21), t(15;17) or inv(16) which exceeded the expression rate in patients with intermediate risk, poor risk or other abnormalities. Information about the clinical outcome was available in 228 patients treated according to the protocols of two German multicenter trials (AML-BFM, AMLCG). We found no difference of CR-rate or event-free survival (EFS) in adults with or without c-kit receptor expression. Children with c-kit receptor negative AML had a lower CR-rate and EFS, but also a lower median age and a higher frequency of M5 subtype as compared to children with c-kit receptor expression. In conclusion, analysis of c-kit receptor expression may help to identify phenotypically immature AML but fails to identify myeloid differentiation of leukemic blasts in approximately one third of patients. We found no evidence of an adverse prognosis in AML patients with c-kit receptor expression. Analysis for c-kit receptor expression does not appear to add information to established prognostic parameters in AML.
Schwartz
S
S
Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Klinikum Benjamin Franklin, Freie Universität, Berlin, Germany. schwart2@zedat.fu-berlin.de
Heinecke
A
A
Zimmermann
M
M
Creutzig
U
U
Schoch
C
C
Harbott
J
J
Fonatsch
C
C
Löffler
H
H
Büchner
T
T
Ludwig
W D
WD
Thiel
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007231:Infant, Newborn; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000235:genetics* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D019009:Proto-Oncogene Proteins c-kit / Q000096:biosynthesis*; D012307:Risk Factors
D019009:Proto-Oncogene Proteins c-kit